NRx Pharmaceuticals (NASDAQ:NRXP) Given “Buy” Rating at D. Boral Capital

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating reissued by D. Boral Capital in a research note issued on Monday,Benzinga reports. They presently have a $34.00 price target on the stock.

A number of other equities research analysts also recently commented on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NRx Pharmaceuticals in a report on Monday, December 29th. Zacks Research raised shares of NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, March 2nd. HC Wainwright upped their price objective on shares of NRx Pharmaceuticals from $40.00 to $45.00 and gave the company a “buy” rating in a report on Tuesday, March 3rd. Wall Street Zen upgraded shares of NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, November 23rd. Finally, Ascendiant Capital Markets reissued a “buy” rating and set a $48.00 target price (up from $47.00) on shares of NRx Pharmaceuticals in a report on Friday, January 2nd. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $38.00.

NRx Pharmaceuticals Price Performance

NRx Pharmaceuticals stock traded up $0.01 during trading hours on Monday, hitting $1.71. 546,183 shares of the stock traded hands, compared to its average volume of 1,112,837. The firm’s 50 day moving average price is $2.08 and its 200-day moving average price is $2.49. The stock has a market capitalization of $54.34 million, a price-to-earnings ratio of -0.73 and a beta of 1.97. NRx Pharmaceuticals has a 1 year low of $1.58 and a 1 year high of $3.84.

Institutional Investors Weigh In On NRx Pharmaceuticals

Several hedge funds have recently bought and sold shares of NRXP. One Wealth Management Investment & Advisory Services LLC increased its stake in shares of NRx Pharmaceuticals by 35.3% during the fourth quarter. One Wealth Management Investment & Advisory Services LLC now owns 37,873 shares of the company’s stock worth $103,000 after purchasing an additional 9,882 shares in the last quarter. State Street Corp raised its holdings in shares of NRx Pharmaceuticals by 14.0% during the 4th quarter. State Street Corp now owns 86,984 shares of the company’s stock worth $236,000 after acquiring an additional 10,700 shares during the period. Ethos Financial Group LLC acquired a new position in NRx Pharmaceuticals in the 3rd quarter valued at about $39,000. Sjbenen Advisory LLC purchased a new position in NRx Pharmaceuticals in the fourth quarter worth approximately $41,000. Finally, Two Sigma Investments LP grew its holdings in shares of NRx Pharmaceuticals by 66.4% during the 3rd quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after purchasing an additional 20,880 shares during the period. Hedge funds and other institutional investors own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.